HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).

AbstractOBJECTIVE:
To evaluate factors affecting sentinel lymph node (SLN) identification after neoadjuvant chemotherapy (NAC) in patients with initial node-positive breast cancer.
BACKGROUND:
SLN surgery is increasingly used for nodal staging after NAC and optimal technique for SLN identification is important.
METHODS:
The American College of Surgeons Oncology Group Z1071 prospective trial enrolled clinical T0-4, N1-2, M0 breast cancer patients. After NAC, SLN surgery and axillary lymph node dissection (ALND) were planned. Multivariate logistic regression modeling assessing factors influencing SLN identification was performed.
RESULTS:
Of 756 patients enrolled, 34 women withdrew, 21 were ineligible, 12 underwent ALND only, and 689 had SLN surgery attempted. At least 1 SLN was identified in 639 patients (92.7%: 95% CI: 90.5%-94.6%). Among factors evaluated, mapping technique was the only factor found to impact SLN identification; with use of blue dye alone increasing the likelihood of failure to identify the SLN relative to using radiolabeled colloid +/- blue dye (P = 0.006; OR = 3.82; 95% CI: 1.47-9.92). The SLN identification rate was 78.6% with blue dye alone; 91.4% with radiolabeled colloid and 93.8% with dual mapping agents. Patient factors (age, body mass index), tumor factors (clinical T or N stage), pathologic nodal response to chemotherapy, site of tracer injection, and length of chemotherapy treatment did not significantly affect the SLN identification rate.
CONCLUSIONS:
The SLN identification rate after NAC was higher when mapping was performed using radiolabeled colloid alone or with blue dye compared with blue dye alone. Optimal tracer use is important to ensure successful identification of SLN(s) after NAC.
AuthorsJudy C Boughey, Vera J Suman, Elizabeth A Mittendorf, Gretchen M Ahrendt, Lee G Wilke, Bret Taback, A Marilyn Leitch, Teresa S Flippo-Morton, Henry M Kuerer, Monet Bowling, Kelly K Hunt, Alliance for Clinical Trials in Oncology
JournalAnnals of surgery (Ann Surg) Vol. 261 Issue 3 Pg. 547-52 (Mar 2015) ISSN: 1528-1140 [Electronic] United States
PMID25664534 (Publication Type: Clinical Trial, Phase III, Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Colloids
  • Coloring Agents
  • Radiopharmaceuticals
Topics
  • Adult
  • Aged
  • Breast Neoplasms (drug therapy, pathology, surgery)
  • Chemotherapy, Adjuvant
  • Colloids
  • Coloring Agents
  • Combined Modality Therapy
  • Female
  • Humans
  • Lymph Node Excision
  • Lymphatic Metastasis
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Prospective Studies
  • Radiopharmaceuticals
  • Sentinel Lymph Node Biopsy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: